# An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

> **NCT06401356** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (estimated)

## Conditions studied

- Hematologic Malignancy
- Solid Tumor
- Advanced Malignancies

## Interventions

- **DRUG:** Pelabresib

## Key facts

- **NCT ID:** NCT06401356
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2027-06-02
- **Final completion:** 2027-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401356, "An Extension Study for Patients Previously Enrolled in Studies With Pelabresib". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06401356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*